EternaGen Labs
For research use onlyCanadian fulfillment · Delivery options at checkout
Back to shop
BPC 157 10mg research compoundEternaGen / Research use only

Peptide · Research use only

BPC 157

$89CAD

An experimental peptide best known for early research into tissue repair, tendon injury and wound response.

Available to approved purchasers

Select strength
1
Documentation review pending Fulfilled in Canada Research use only

Can’t find the right record?Send support the product name or batch code.

Contact support
BPC 157$89

Product information

BPC 157, clearly explained.

An experimental peptide best known for early research into tissue repair, tendon injury and wound response.

Overview

Researchers are interested in how BPC 157 behaves in models of tissue repair, tendon injury and wound response. Almost all of that work has been done in cells and animals, so we still do not know whether the same effects occur in people.

BPC 157 is a synthetic 15-amino-acid peptide. Most published research is made up of cell, tissue and animal experiments rather than adequately controlled human trials.
Format
Vial
Available strengths
10mg
Documentation
Source review pending
Research at a glancePreclinical evidence; human efficacy not established
Reviewed 23 July 2026View research context

Specifications

Product details

Sequence / identity
GEPPPGKPADDAGLV
Molecular formula
C62H98N16O22
Molecular weight
1419.56 g/mol
Storage and handling
Store lyophilized material according to the conditions stated on the batch record. Protect from light and moisture.
Batch documentationSource review pending

Supplier-origin documentation will be published only after EternaGen verifies the source and record details.

Not yet published
Important research-use boundary

Health Canada lists the named compound or components among unauthorized injectable drugs identified in the Canadian market. A research-use label does not make an unauthorized product suitable or legal for personal use.

Explore the research

What has been studied?

Keep the context attached

Check what was studied, what researchers observed, and the limitation attached to each finding.

Question 01

Tendon and connective-tissue models

Rat tendon-transection and cultured-tendocyte studies report changes in biomechanical recovery, cell migration and stress survival.

Evidence so far: Animal and laboratory models
Question 02

Wound-response pathways

Preclinical papers explore angiogenesis, fibroblast activity and nitric-oxide-related signalling after experimentally induced injury.

Evidence so far: Hypothesis-generating evidence
Question 03

Human outcomes

Robust randomized human evidence for musculoskeletal recovery, gastrointestinal disease or systemic use has not been established.

Evidence so far: Major evidence gap

Proposed mechanism

How researchers are investigating the mechanism.

Experimental work has examined cell migration, survival under oxidative stress and signalling involving focal adhesion kinase and paxillin. These are mechanistic observations, not proof of healing or recovery in people.

Evidence gaps

What remains unknown?

  • No established therapeutic indication or adequately characterized benefit-risk profile for human use.
  • Human pharmacokinetics, route-specific safety and long-term adverse effects remain insufficiently characterized.
  • Findings from one experimental formulation cannot authenticate or predict the performance of a separately sourced material.

Primary sources

Check the original sources.

  1. Primary preclinical studyStaresinic et al. Rat Achilles tendon and tendocyte study. J Orthop Res. 2003. PMID 14554208.
  2. Regulatory safety reviewU.S. FDA. Certain Bulk Drug Substances That May Present Significant Safety Risks: BPC-157.
  3. Canadian public advisoryHealth Canada. Think twice before injecting peptides bought online. 9 April 2026.

Related products

Continue comparing.

Browse all products